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Data analysis and interpretation
of results in DATAS trial
Regarding the DATAS randomized study by
Almendral et al., 1 we would like to comment
on methodological issues that may limit the
validity of the results of this trial.
The investigators have created clinically
signiﬁcant adverse events (CSAEs) scoring
system2 based on assigning arbitrary
weights to actual events that may artiﬁcially
change the value of the analysed events,
thus creating the potential of converting
statistically insigniﬁcant result into a signiﬁ-
cant one. It is understandably difﬁcult to
model the outcome death, using such a
CSAE scoring system and therefore the
results could potentially underestimate the
lethality of the interventions. Another
source of modifying the observed difference
between the two groups is the method of
‘penalizing’ for crossovers. Adding scores to
both groups may not fully compensate for
right censored data, but could artiﬁcially
modify the difference between groups.
Furthermore, as paroxysmal atrial tachy-
cardia was not an exclusion criterion, and
dual-chamber (DC) implantable cardioverter
deﬁbrillators (ICDs) offered atrial anti-
tachycardia functions, not surprisingly
patients with single-chamber (SC) devices
may experience a higher rate of long-
duration atrial tachycardia. However, if
some patients in the DC-ICD group received
anti-tachycardia pacing or atrial shock, it is
unclear whether this adverse event was not
a reason for some crossovers. Given higher
rates of both appropriate and inappropriate
shocks in the DC-ICDs compared with
SC-stimulated devices reported previously,3
analysis of the causes of inappropriate
shocks would be interesting.
Considering primary indications for ICD
implantation, current registries show differ-
ent rates of primary indications in different
countries.4 The DATAS sample population
results may therefore have limited general-
izability to other populations with conven-
tional indications for ICD implantation.
Finally, as quality of life was to be evalu-
ated as a secondary objective according to
the study design,2 it would be interesting
to the readers to see these data published.
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Data analysis and interpretation of
results in DATAS trial: reply
We appreciate the letter from Vardanyan
and Kanna, which provides us with the
opportunity to clarify some issues about
the DATAS trial.
Studies comparing dual-chamber (DC) and
single-chamber (SC) implantable cardiover-
ter deﬁbrillator (ICD) have so far focused
on a single aspect of ICD therapy. Our aim
was a global evaluation of their ability to
reduce the clinically signiﬁcant adverse
events (CSAE) frequently suffered by ICD
patients. Thus, we faced the challenge of
evaluating patient outcome by a single vari-
able. This would allow to (i) concentrate on
alpha risk and (ii) have only one interpret-
ation of the results as an answer to the
objective question ‘do DC-ICDs improve
patient outcome by reducing CSAE?’
As patient evolution has to consider differ-
ent undesired events, we decided to deﬁne a
composite end-point, and that was men-
tioned in the DATAS design manuscript.1
This strategy has two advantages: ﬁrst, the
possibility to concentrate patient evolution
in a single measure. This requires the
assumption of clinical homogeneity,2 i.e.
that only aspects of similar medical rel-
evance are pooled together and second,
the chance to increase the study power
allowing for smaller sample sizes. The
required assumption is that of statistical
homogeneity.3
The two ‘softer’ CSAE, i.e. inappropriate
shocks and atrial tachyarrhythmias (AT),
were ‘hardened’ in number and duration,
respectively, to reinforce their clinical rel-
evance. However, we believed that the
assumption of clinical homogeneity was not
met if death was pooled together with the
other CSAE. We wanted to avoid, for
example, that a patient with three hospital-
izations had a worse score than a patient
who died. The developed scoring system
ensured that death, the worst expected
outcome, had the highest score. Unplanned
crossovers, a failure of the allocated treat-
ment, received a relatively high score.
Although it has been demonstrated a
higher rate of AT during follow-up in patients
having them previously, this is presently
neither a contraindication for ICD therapy
nor an indication for DC-ICD. Thus, it was
appropriate and justiﬁed to measure the
potentially more active role of DC-ICD
against AT. As described in the manuscript,
inappropriate discharges were never a
reason for premature crossover.
DATAS ICD indications, in accordance to
contemporary guidelines, included second-
ary prevention in more than 85% of patients.
Thus, the extent to which DATAS results
could also apply to primary prevention
patients is unclear.
We agree with Vardanyan and Kanna in the
interest of the quality of life results, pre-
sently undergoing analysis.
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